Eloquest Healthcare has signed an agreement to promote Omni-stat Medical’s haemostatic products portfolio within the US acute-care market, focusing on vascular access procedures and intensive care units (ICUs).

The haemostatic gauze products swiftly control bleeding and provide support to clinicians in critical care settings where reliability and time are essential.

The introduction of these solutions is in line with Eloquest Healthcare's mission to elevate standards of care and enhance patient outcomes in vascular access management.

Eloquest Healthcare president and CEO Tim O'Halla said: “We are excited to partner with Omni-stat Medical to bring these proven haemostatic solutions into more hospitals and ICUs across the country.

“This agreement reflects our continued commitment to aligning with best-in-class technologies that complement our portfolio. Together, we can help clinicians improve care and outcomes for patients at some of the most challenging points in their treatment journey.”

Eloquest Healthcare, a subsidiary of Ferndale Pharma Group, provides solutions that improve clinical outcomes, enhance the quality of care, reduce overall healthcare costs, and increase staff efficiency.

Omni-stat Medical US commercial operations director Gina Milner said: “Omni-Stat is proud to collaborate with Eloquest Healthcare. Their deep expertise and trusted presence in the acute-care market make them the ideal partner to expand adoption of our haemostatic products.

“We look forward to working together to support clinicians with more efficacious solutions that rapidly reduce blood loss and save time, ultimately improving safety, and enhancing patient care.”

Omni-stat Medical specialises in haemostatic technologies that are designed for the control of severe, minor, and moderate bleeding.